Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AEKGE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU2023281032A1 ADC-5
|
|||||
| Synonyms |
AU2023281032A1 ADC-5
Click to Show/Hide
|
|||||
| Organization |
GENEQUANTUM HEALTHCARE (SUZHOU)CO.,LTD[CN/CN]
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.87
|
|||||
| Antibody Name |
anti-TROP2 antibody
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
AU2023281032A1 ADC-1 linker
|
Linker Info | ||||
| Conjugate Type |
site-specific conjugation
|
|||||
| Combination Type |
LP-2
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal inhibitory Concentration (lC50) |
0.1017
|
nM
|
CVCL_0186
|
Pancreatic ductal adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
25.61%
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cell (the maximum killing percentage relative to the control group) in HepG2
|
||||
| In Vivo Model | HepG2 CDX Mouse Model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
72.22%
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cell (the maximum killing percentage relative to the control group) in FaDu
|
||||
| In Vivo Model | FaDu CDX Mouse Model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.21%
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cell (the maximum killing percentage relative to the control group) in BxPC-3
|
||||
| In Vivo Model | BxPC-3 CDX Mouse Model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.21%
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cell (the maximum killing percentage relative to the control group) in BxPC-3
|
||||
| In Vivo Model | BxPC-3 CDX Mouse Model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.1017 nM
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM) in BxPC-3
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
References